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A FRONTIERS objective is to extend operations research (OR) into new areas such as 
sustainability research and social marketing. This project marks a departure into these 
areas. 
 
CEMOPLAF of Quito, Ecuador sells reproductive health products to pharmacies and 
other outlets to contribute to the sustainability of the not-for-profit agency.  CEMOPLAF 
lacked basic information regarding the program’s profitability, niche, and quality.  OR to 
provide this information included a financial analysis of the marketing program and two 
market research studies.  Each study included a capacity building component so that 
CEMOPLAF could conduct similar studies in the future without technical assistance.  A 
regional conference attended by non-governmental organizations (NGOs) was also 
included.  The conference objective was to share sustainability tools and lessons learned.  
The Commercial Market Strategies (CMS) project co-sponsored the conference.     
 
Marketing Project Profitability Analysis:  The study found that the marketing program 
was profitable during the calendar year 1998, generating $103,000 in net profits.  Return 
on sales revenue was 10 percent.  The condom brand Protektor brought in the most 
revenue of any product, and contributed the highest total gross profits.  Protektor’s 
dominance was due to high sales volume, since the product is near to the bottom of the 
list of net revenue per unit sold.  Half of the sales force was responsible for nearly all of 
the profits, and most of these agents worked in Quito-Guayaquil.  Major 
recommendations implemented by CEMOPLAF included shifting from sales revenue to 
gross profit as an indicator of sales agent success, and a change from a salary-based 
compensation system to a more heavily commission-based compensation system for sales 
agents.  Other important long-term impacts of this study include: (a) SM executives 
learned to use the tools introduced in this study to routinely analyze financial 
performance from a profitability perspective; and (b) sales agents now have access to 
information for tracking unit profit margins, trends in sales volume, and the financial 
performance of their own regions.  
 
Marketing Project Client Profile: The study was conducted in a sample of pharmacies in 
five cities.  Results indicate that purchasers of CEMOPLAF contraceptives are of lower 
socio-economic status than are purchasers of other contraceptive brands, and of 
purchasers of non-contraceptive products in the pharmacies studied.  Information on non-
CEMOPLAF products purchased by customers was also obtained from the study, as was 
information on products that were frequently sought but also frequently out of stock in 
the pharmacies. This data helped CEMOPLAF decide to market higher margin, non-
reproductive health products (including those frequently out of stock) directed at the 
pharmacies’ more affluent clients.       
 
Quality of Information Provided to CEMOPLAF Customers:  Mystery shoppers 
purchased CEMOPLAF oral contraceptives, DMPA and pregnancy tests from a 
representative sample of pharmacies. This study revealed that pharmacists behave very 
 
much like clinical providers of family planning methods; they provide clients with 
method use instructions, but little or no information about side effects and 
contraindications.  However, information on these aspects of method use was increased 
when clients asked specific questions of the pharmacists.  Due to lack of funds, the 
recommended intervention to increase information transfer - posters reminding clients to 
ask the provider about contraindications and side-effects - could not be implemented.  
 
Capacity Building Activities:  As a result of the financial analysis, CEMOPLAF 
marketing managers learned to gather and use profit data to make decisions regarding 
individual sales agents, specific products and overall program direction.  FRONTIERS 
assistance also included three workshops for 28 program staff on market segmentation, 
sales techniques, and billing and receiving. A local expert taught each workshop.  
CEMOPLAF research staff learned to conduct point of purchase surveys, mystery client 
studies, and financial analyses.  Other agency staff gained experience as interviewers and 
mystery clients, leaving the agency with the infrastructure needed to conduct future 
market research.        
 
Latin American Regional Conference on Sustainability and Social Mission: More than 80 
individuals registered to attend the conference.  They represented over 40 family 
planning organizations, research organizations, pharmaceutical companies, and donors.  
The conference objectives were to: 
• Share sustainability research and lessons learned;  
• Share experiences of NGOs that have attempted to improve the sustainability of 
programs while maintaining their commitment to social mission; and 
• Provide NGOs and companies that market reproductive health products the 
opportunity to explore the possibility of commercial agreements. 
 
Evaluation of the conference was positive, with almost 90 percent of participants rating it 
as “useful” or “very useful.”  CMS and FRONTIERS are in the process of planning a 
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Operations research (OR) has played an important role in all types of family planning and 
reproductive health service delivery modalities with the exception of social and commercial 
marketing programs where research has been limited mainly to market surveys.  The current 
movement towards sustainability is causing social marketing (SM) programs to examine issues 
like profitability, productivity and quality.  This provides an opportunity for extending OR into 
the social marketing of reproductive health products and services.   
  
CEMOPLAF of Quito, Ecuador is an excellent laboratory for introducing OR into social 
marketing.  The agency is experienced in operations research and uses it in making important 
program decisions.  CEMOPLAF is a leader in sustainability activities in Latin America, and its 
staff is frequently called upon by other organizations in the region to provide technical 
assistance. Finally, the agency has a rapidly growing social marketing program that accounts for 
36 percent of agency revenues.  CEMOPLAF is depending on SM to become the major force in 
agency sustainability, and wishes to use OR to both improve profitability and quality and 
increase program scope. 
 
FRONTIERS initiated a long-term relationship with the CEMOPLAF commercial marketing 
program with a two and a half year  (February 1999 – August 2001) project that included both 
diagnostic studies and capacity building activities. Three studies were conducted: (1) an 
assessment of program profitability and productivity; (2) a determination of the profile of retail 
purchasers of CEMOPLAF products; and (3) an evaluation of the quality of information 
provided to retail purchasers of SM contraceptives.  The diagnostic studies are intended to lead 
to a subsequent round of intervention research to improve productivity, introduce new products 
and improve the quality of information given to retail purchasers.  Capacity building activities 
included marketing seminars for SM project staff (none of whom were marketing professionals), 
and training in the design, conduct and analysis of mystery client research.  Finally, a regional 
seminar on sustainability for not-for-profit reproductive health programs, co-sponsored with the 
USAID funded Commercial Market Strategies (CMS) project was held in Ecuador in May 2001.  
This final report includes information on the three research projects conducted by CEMOPLAF 
as well as on the capacity building activities and the regional seminar. 
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STUDY I: A FINANCIAL ANALYSIS OF THE CEMOPLAF 
SOCIAL MARKETING PROGRAM 
Author: John Bratt 
 
I.  Introduction 
 
A.  Background 
 
Reproductive health programs in developing countries face a major challenge: to provide a 
greater variety of products and services to a rapidly increasing number of users.  This challenge 
must be met in the context of stagnant or decreasing donor funding.  One strategy for providing 
more services to more people in the face of scarce resources is to shift clients out of highly 
subsidized services (such as those provided by government programs) to social marketing 
programs, and ultimately to the commercial sector. 
 
Social marketing has become an increasingly prevalent mechanism for delivering family 
planning and reproductive health services.  In the Latin America and Caribbean (LAC) region, 
for example, virtually every country receiving USAID funding in recent years has a social 
marketing program.  These programs occupy a middle ground between the public and for-profit 
sectors.  They serve individuals with sufficient resources to pay something for services, although 
not full commercial sector prices.  
 
Because of sustainability concerns, many social marketing programs are now pursuing strategies 
to add for-profit product lines in order to cross-subsidize products that are sold at subsidized 
prices, or even to cross-subsidize clinical or community based (CBD) programs.  But little 
research exists to guide program managers in deciding how to proceed.  For example, in almost 
15 years the Latin American Operations Research Projects (INOPAL) conducted only three 
studies with social marketing programs, while carrying out approximately 150 studies with 
clinical and CBD programs.   SM programs have focused their research activities on market 
surveys, but little sustainability or quality improvement research has been published. 
 
B.  Program Setting 
 
CEMOPLAF is a non-governmental (NGO), not-for-profit organization that operates several 
reproductive health programs throughout Ecuador, including 21 clinical centers, a rural CBD 
program, and special programs for adolescents, commercial sex workers, men and indigenous 
groups.  The organization has become known as a leader in sustainability activities in Latin 
America.  CEMOPLAF recovers approximately 80 percent of total operating costs through client 
fees, and staff are consultants to other LAC reproductive health programs.  CEMOPLAF also 
uses operations research as a routine decision making tool.   
 
In 1996 CEMOPLAF launched its first social marketing project; by 1998 social marketing 
became the largest single source of locally-generated funds, accounting for approximately 36 
percent of gross revenue ($67,000 per month).  The SM project sells contraceptive and 
reproductive health products to pharmacies, physicians, other distributors and non-traditional 
outlets including liquor stores, hotels, motels and brothels.  At the end of 1998 the SM project 
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was selling 36 different products, most of which were purchased locally from pharmaceutical 
supply houses.1  In terms of unit sales, the most important are pills (234,000 cycles per year), 
condoms (800,000 packages of three per year), injectable contraceptives (100,000 doses per 
year), and home pregnancy tests (40,000 tests per year).  SM executives plan to gradually expand 
the list of products offered. 
 
In 1998 the project employed 29 full and part-time workers and deployed sales agents in 14 of 
the 16 cities where CEMOPLAF operates clinics.  But rapid growth had left the project with 
inadequate infrastructure and procedures, particularly for analyzing financial performance.  
Plans existed for introducing a computerized management information system, but in 1998 
project staff were still using a manual system, making basic financial analysis very 
cumbersome.  Moreover, the project had not yet identified basic indicators for assessing overall 






The specific objectives of this study were to: 
 
• Conduct a financial analysis to measure profitability of the social marketing project and of 
individual sales agents; and 
• Build capacity for financial analysis within the program so that future studies could  be done 
with minimal external assistance. 
 
The study contributed to the achievement of FRONTIERS' Intermediate Result 3, "capacity for 
problem solving enhanced within organizations."  Prior to the study, decision making in the 
CEMOPLAF social marketing program was not supported by information on profitability or 
productivity.  It is expected that future decisions will be informed by data on profitability and 
productivity.  The project also contributed to USAID/Ecuador's Intermediate Result 1, 
"increased sustainability of family planning NGO partners" by strengthening CEMOPLAF's 
financial control over its SM project, and by explicitly placing strategic emphasis on profitability 
as the main measure of success. 
 
 
III.  Methods 
 
The unit of analysis in this study was the social marketing sales agent.  We used a “bottom-up” 
costing approach to identify and value all of the resources used by sales agents and other 
CEMOPLAF staff to market SM products.  Detailed information follows on methods used to 




                                                 
1 USAID continues to donate contraceptive methods to the program, including condoms, pills, IUDs and injectables. 
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A.  Program Costs 
 
1.  Contraceptives, medicines and other products 
 
CEMOPLAF purchases most SM products from local suppliers of pharmaceuticals.  In 
Ecuadoran commerce, it is common practice for suppliers to deliver more units than a customer 
actually purchases (usually 10 – 20 percent more) as an incentive for future business.  These 
bonus units reduce CEMOPLAF’s actual per-unit product cost below the official price negotiated 
with suppliers.  SM accountants reviewed purchase records and calculated unit cost for each 
product by dividing the total amount paid by the number of units entered into inventory.  In this 
way, unit product costs were adjusted downward to reflect the value of the “bonus units” added 
to the order by the supplier.  Because of volatility in the Ecuadoran economy, product costs were 
increasing at different rates throughout 1998.  It was therefore necessary to calculate unit product 
costs separately for each month of the year. 
 
Estimated unit costs of donated contraceptives were imputed by determining the cost of 
purchasing similar products and then adding labor and materials costs to repackage the products. 
 
2.  Sales agent compensation 
 
CEMOPLAF accountants provided information on salaries, benefits and sales commissions paid 
to sales agents in 1998.  Total compensation per agent was calculated by summing nominal 
salary, the 12 separate benefit categories required by Ecuadoran law, and sales commissions. 
 
3. Administrative support in CEMOPLAF clinics 
 
Sales agents in all regions except Quito are physically situated in small offices located within 
CEMOPLAF clinics.2  Administrative staff in these clinics provide varying levels of supervision 
and accounting support to sales agents.  We visited each clinic and conducted interviews to 
determine the proportion of time spent by individual staff members assisting the SM program.  
The cost of this time was calculated for each administrative staff person by multiplying total 
annual compensation by the percentage of annual work time dedicated to SM. 
 
4. Other operating costs 
 
Sales agents incur a range of other costs in the course of marketing SM products.  These include 
costs of transport, per diem, product-specific advertising, etc.  Moreover, the SM program 
invests resources annually to organize training seminars and meetings for staff.  Information on 
these costs was provided by SM accountants.  When feasible, costs corresponding to specific 
sales agents were taken directly from expenditure records (for example, transport and perdiem, 
office supplies); costs of resources that benefit the entire SM program (training, advertising) 




                                                 
2 In Quito, the 10 sales agents occupy space that is contiguous with the Social Marketing executive office. 
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5. Infrastructure and equipment 
 
Sales agents were assigned a portion of building rent, utilities and housekeeping costs 
corresponding to the percentage of the CEMOPLAF clinic floor space occupied by the SM 
office.  In facilities owned by CEMOPLAF, we calculated an estimate of equivalent rental value 
per square meter by averaging the rental charges per square meter in leased facilities.   
 
Annualized costs of office furniture were estimated under the assumption that each sales agent 
used a basic grouping of a desk, a chair and a filing cabinet.  Sales agents also use personal 
computers for inventory management, record-keeping and reporting.  In Quito, each sales agent 
has exclusive use of a PC, and therefore was assigned the entire annualized cost.  In other sites 
computer resources are shared with clinic staff.  Our approach was to assign a portion of the 
annualized computer cost corresponding to the percentage of time that clinic administrative staff 
dedicated to the SM program, since the time spent was mainly used to input SM data into the 
computer.  Finally, the SM program owns a vehicle that is used exclusively to support the efforts 
of the ten sales agents working in Quito.  The cost of this vehicle was annualized, and divided 
equally across these ten sales agents. 
 
B. Sales Revenue 
 
The SM program charges its customers (pharmacies and physicians) a negotiated price for each 
unit sold, and also offers in-kind bonuses (usually 10 percent) to encourage future sales.  
Program accountants provided price lists for each product, by month.  Sales revenue for each 
month was calculated by multiplying the corresponding unit price for each product by the 





A. Overall Profitability 
 
The objective of the social marketing program is to produce profits that can be used to support 
other CEMOPLAF programs.  Table 1 provides information on total revenue, total costs and net 
profit for 1998.  Sales of products generated revenues of 5.6 billion sucres (approximately 
US$1.3 million at the average 1998 exchange rate).  CEMOPLAF paid over 3.9 billion sucres 
(US$715,000) to acquire these products from suppliers, leaving a gross profit of nearly 1.7 
billion sucres (US$300,000).  Costs of running the program – including sales, marketing and 
management – totaled 1.1 billion sucres (US$198,000).  Net profit for 1998 was 563 million 
sucres (US$103,000), representing a 10 percent return on sales volume.  
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Millions of 1998 Sucres 
   
Sales Revenue 5,631  
  Cost of Goods Sold 3,967  
   
Gross Profit 1,664  
   
Other Program Costs   
 Personnel 612  
 Training 23  
   Advertising 94  
   Other Recurrent Costs 95  
   Equipment 33  
   Infrastructure 79  
   Program Overhead 165  
   
Total Other Program Costs 1,101  
   
Net Profit 563  
 
B. Uses of Program Income 
 
Figure 1 consolidates information in Table 1 to provide a graphical representation of how 
CEMOPLAF used the income generated by the SM program in 1998.  Seventy percent of sales 
revenue was used to cover product costs.  Program costs (including staff, supplies, advertising 
and other costs) and program overhead consumed an additional 20 percent, leaving a profit 
margin of 10 percent. 
 















C. Differences in Net Revenue by Product 
 
In 1998 the SM product list included 36 different items, of which 19 were contraceptive 
methods.3  Table 2 presents information on net revenue per unit for a subset of products.  Net 
revenue is defined as sales revenue minus product cost, and represents the margin earned from 
each unit of sales that is available to cover other program costs.  Net revenue varies substantially, 
from a high of US$4.00 to a low of US$-0.02; average net revenue per unit is US$1.46.  The 
highest-selling brands tend to be those with lower per-unit margins, such as the Protektor 
condom brand and LoFemenal oral contraceptives. 
 
Table 2: Net Revenue per Unit for Selected Social Marketing Products, in 1998 Sucres 
($US1 = 5450 S/.) 
 
Top Five 
Net Revenue per Unit 
(US$ in parentheses) 
    Clamox cream 21,840  (4.00) 
    Mobic 15 20,400  (3.74) 
    Gynera CD 19,748  (3.62) 
    Marvelon 18,450  (3.39) 
    Clamox  18,159  (3.33) 
Bottom Five  
    Protektor 2,412  (0.44) 
    Copper T 380A 1,726  (0.32) 
    LoFemenal 1,542  (0.28) 
    Nordette MD 936  (0.17) 
    Conceptrol - 95  (-0.02) 
Average of all Products 7,936  (1.46) 
 
D. Profitability by Region 
 
Approximately half of the SM sales agents work in either Quito or Guayaquil (the two major 
urban areas of Ecuador), while the remaining agents work in smaller cities.  Figure 2 shows 
differences in productivity and profitability between the two regions.  The lighter-shaded bar 
represents gross profit, which equals sales revenue minus product costs (the same concept as net 
revenue, only on an aggregate basis).  The darker bar represents program costs, which equal total 
SM costs excluding product costs.  Agents working in Quito–Guayaquil produced nearly twice 
as much gross profit as agents working in smaller cities, and accounted for more than 80 percent 
of SM total net profits (shown by the difference between the gross profit and and program cost 
bars).    
 
                                                 
3 These methods included 11 brands of OCs, five formulations of injectables, one brand of condoms, an IUD and a 
contraceptive foaming tablet. 
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Figure 2:  Gross Profit and Non-product Costs of Social Marketing 

















Gross Profit Non-product Costs
 
 
Differences between the two regions in productivity and profitability are related to sales volume 
and to a lesser degree, composition of sales.  All agents incur the same product costs, and 
program costs are similar between the two regions.  The key factor is gross profit; each agent 
must produce approximately S/. 45 – 50 million (US$8,200 – $9,200) in gross profit in order to 
break even.4  Gross profits can be increased by selling more products overall (sales volume) or 
selling more of the most profitable products (composition of sales).  Since the Quito-Guayaquil 
region has a larger number of potential SM customers (pharmacies and physicians) and a more 
diverse and commercialized market, it is easier for sales agents to generate gross profits (and 
therefore net profits) in this region. 
 
E. Profitability of Sales Agents 
 
Figure 3 presents information on profitability of CEMOPLAF’s 25 sales agents.  Each data point 
represents one sales agent, and points are divided according to the two main regions: black 
diamonds correspond to agents working in Quito-Guayaquil, and gray dots represent agents 
working in other cities.  The diagonal line shows all possible points where the agent “breaks 
even”, i.e. where gross profit (sales revenue minus product cost) exactly equals program costs.  
Points lying above the diagonal line indicate profitable sales agents.  All but two of the Quito-
Guayaquil sales agents earned net profits, while the majority of agents working in other cities 
either lost money or earned small net profits.5 
 
                                                 
4 Gross profit is more useful as an indicator of productivity than sales revenue, because unit profit margins vary 
substantially across products.  As an example, consider the difference between two agents: one sells US$20,000 in 
low-margin products, and generates gross profits of US$5,000; the other sells US$15,000 in high-margin products 
and generates gross profits of US$7,000.  The first agent produces more sales revenue, but the second agent 
generates more net revenue. 
5 Notable exceptions included sales agents in Riobamba (Jaramillo), Latacunga (Mayorga), and Santo Domingo 
(Aguirre). 
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Figure 3:  Profitability of Individual Sales Agents, by Region, 






















1. The social marketing project was profitable during the calendar year 1998, generating 
$103,000 in net profits to be used by CEMOPLAF management to support other 
activities.  Return on sales revenue was 10 percent.  We cannot say how this result 
compares with financial performance of other SM programs because our literature 
searches found no references to other studies on profitability of social marketing.  But 
even if such studies do exist, it is unlikely that results would be comparable because of 
the economic cost focus used in our study. 
 
2. The condom brand Protektor brought in the most revenue of any product, and contributed 
the highest total gross profits.  Protektor’s dominance was due to high sales volume, since 
the product is near to the bottom of the list of net revenue per unit sold.   
 
3. Half of the sales force is responsible for nearly all of the profits, and most of these agents 
work in Quito-Guayaquil.  Seven of 25 agents lost money. 
 
4. Other important long-term impacts of this study include: (a) SM executives now have the 
tools to analyze financial performance from a profitability perspective; (b) sales agents 
will have access to better information for tracking unit profit margins, trends in sales 
volume, and the financial performance of their own regions.  
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B.  Recommendations 
 
1. The SM program should use gross profit as the key indicator of productivity for sales 
agents.  Gross profit is a better indicator of success than sales revenue, because sales 
revenue does not account for product costs.   
 
2. The SM program should evaluate current compensation policy for sales agents.  Sales 
bonuses range from 0% to 10 percent of salaries, with most sales agents clustered in a 1 – 
3 percent band.  It is unlikely that this bonus structure serves as a real incentive to agents 
to sell more products.  One idea would be to test an alternative compensation policy 
where fixed salaries were substantially reduced, and sales agents were given opportunity 
to earn substantial bonuses on gross profit. 
 
3. The SM program should assess whether some of the smaller cities have a large enough 
market to justify a dedicated SM presence, and consider eliminating or consolidating 
sales areas. 
 
4. The SM program should routinely collect, analyze and distribute information similar to 
the data generated in this study.  For example, sales agents should have current 
information on net revenue by product, to know which products contribute the most to 
profitability.  Also, the SM program could make annual projections of non-product costs 
for each sales agent (i.e., salary, transport, training, etc.) and then provide feedback to 
sales agents on gross profits generated each month.  Such a system would allow SM 
management and each sales agent to track progress toward the break-even point. 
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STUDY II: MARKET ASSESSMENT FOR CEMOPLAF 
PRODUCTS:  CUSTOMER PROFILE 
Authors:  Dr. Laura C. Altobelli and Ana María Buller 
 
I.  Introduction 
 
Social marketing is recently becoming recognized as an important channel for delivering family 
planning and reproductive health services.  It is a service-delivery strategy that has developed out 
of the increasing demand for these services in the face of ever decreasing donor support.  The 
strategy involves shifting clients from government programs to partially subsidized social 
marketing programs, and eventually to the commercial sector.  Target clients are those who have 
sufficient resources to pay something for services, although not full commercial sector prices.  In 
order to strengthen program sustainability, social marketing programs are now moving more into 
commercial marketing by adding for-profit product lines in order to cross-subsidize products or 
services that are sold at lower, subsidized prices.   
 
CEMOPLAF of Quito, Ecuador is a private non-profit organization that provides reproductive 
health services and products.  The organization has grown to include 21 reproductive health 
clinical centers, a rural CBD program, and special programs for adolescents, men, and 
indigenous groups in 14 cities of Ecuador.  In the area of program sustainability, CEMOPLAF 
serves as a model for Latin America.  Over 80 percent of CEMOPLAF costs are recuperated.  
The largest portion of cost-recovery comes from social marketing activities.  CEMOPLAF sells 
contraceptive and reproductive health products to pharmacies, physicians, other distributors, and 
non-traditional outlets including liquor stores, hotels, motels and brothels.   
 
Within FRONTIERS’ global research agenda in sustainability, CEMOPLAF has been identified 
as a key program for developing and conducting operations research in social marketing for 
sustainability.  CEMOPLAF wishes the program to become more commercial and capable of 
generating income that will be used to subsidize other projects.  To do so, CEMOPLAF will have 
to build market share, add products, and expand into new markets.  One of the steps for 
CEMOPLAF to reach this goal is to better understand its products’ market share, the size of the 
market for them, the socio-demographic profile of the current and potential purchasers of its 
products, and other aspects including analyses of finances and quality of services.    
 
The present document is a report on a market assessment study conducted to profile the 
customers in commercial pharmacies where CEMOPLAF products are sold.   
 
 
II.  METHODOLOGY 
 
We conducted point of purchase interviews in five cities with the largest market for CEMOPLAF 
products:  Quito, Guayaquil, Santo Domingo de los Colorados, Riobamba, and Ambato.  




A.  Sample Selection 
 
Sampling was done in two stages.  A random sample of retail outlets selling CEMOPLAF 
projects was drawn in each of the five cities.  The number selected was roughly proportional to 
the city’s population: 15 in Quito, 15 in Guayaquil, 10 in Santo Domingo, 5 in Riobamba, and 5 
in Ambato for a total sample of 50 retail pharmacies.  The sample in each city was stratified by 
size of the pharmacy (large, medium, and small), determined by the average number of 
customers per day.1  All persons exiting the selected pharmacies during pharmacy hours were 
interviewed for a period of five consecutive days.  All exiting customers who had made a 
purchase in the pharmacy were asked to respond to the full questionnaire.2  The total number of 
interviews of purchasing customers was 8,942.    
 
B.  Data Collection  
 
Interviewers were CEMOPLAF personnel who had received prior training in interviewing 
techniques.  The questionnaire consisted primarily of closed-ended questions.  Information was 
collected on the interviewee’s sociodemographic characteristics, home and work location, reason 
for purchasing in that particular pharmacy, medicine or product purchased that day, intended 
recipient, ability to find all desired products, and those that had not been found. 
 
 
III.  Results 
 
A.  Socioeconomic Characteristics of Study Population 
 
The socioeconomic characteristics of the study participants differed among the five cities, as 
shown on Table 1.  Education was positively associated with size of the city.  Guayaquil had the 
best-educated pharmacy clientele at 77.2 percent with secondary or higher education, followed 
by Quito with 68 percent.  The smallest city studied, Ambato, had the lowest percentage with 
secondary or higher education (59.5%), as well as the highest proportion of clients with no 
formal education (8%).  Educational level is important when considering what type of 
advertising and promotion is most effective. 
 
Pharmacy clients had a median age of 33 years, though the distribution in each city varied.  
Santo Domingo had a significantly lower proportion of persons over 45 than the other four cities. 
This has implications for the types of pharmaceutical products they would be likely to purchase. 
 
In all cities, females were more likely than males to be pharmacy purchasers.  Size of city was 
associated with male purchasing, ranging from a high of 48 percent male purchasers in 
Guayaquil to a low of 39.1 percent male in Riobamba (Table 1). 
 
                                                 
1 The sample of pharmacies utilized was the same as that used for the mystery client study. 
2 The first day of data collection, interviewees received a small incentive gift for their participation.  This was 
immediately identified as a stimulus for repeat purchases, and the practice was stopped for the remainder of the 
study. 
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Percentage of married or in-union pharmacy users ranged from 62 percent in Guayaquil to 71.1 
percent in Ambato.  The remainder was single or had ‘other’ civil status. 
 
Interviewees reported up to three different products purchased.  If any one was a CEMOPLAF 
product, the person was coded as a CEMOPLAF purchaser.  The highest proportions of 
CEMOPLAF product buyers were in Santo Domingo with 11.7 percent and Riobamba with 8.9 
percent.  The lowest percentage (3.9%) was in Guayaquil. 
  
Table 1:  Characteristics of Study Population in Pharmacies by City 
CITY* 
Characteristics of users 
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Source of products purchased 
CEMOPLAF product 
















N = 2993 2675 586 942 1746 
* Quito – Capital of Ecuador in Andes mountains. 
   Guayaquil – Principal commercial/shipping center for Ecuador on coast. 
   Santo Domingo – Medium size provincial capital on inland coast.  
   Riobamba – Medium size provincial capital in Andes mountains. 




1.  Profile of Pharmaceutical Purchasers - CEMOPLAF versus Non-CEMOPLAF 
 
For market identification purposes it is useful to investigate whether there are any differences 
between the characteristics of people buying CEMOPLAF products and those buying products 
from other sources.   
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Table 2 presents a comparison of characteristics of CEMOPLAF product buyers and purchasers 
of other products.   According to the table, there was no significant difference in education 
between the two groups. 
 
Table 2:  Profile of All Pharmacy Purchasers by Source of Products Purchased 
 
SOURCE OF PRODUCTS 
Characteristics of users 






















  <15 
15 – 24 
25 – 34 
35 – 44 































N = 619 8323  
There was a significant difference in age between the two groups.  About 84 percent of 
CEMOPLAF purchasers were 15 to 44 years of age, with just 70.2 percent of non-CEMOPLAF 
product purchasers in this age group.  The age difference is likely due to CEMOPLAF’s 
concentration on selling contraceptives and other products used by women of fertile age.  
CEMOPLAF purchasers were significantly more likely than other product buyers to be female, 
as is consistent with the reproductive health orientation of the CEMOPLAF product line.  
 
2.  Profile of Contraceptive Purchasers – CEMOPLAF versus Non-CEMOPLAF 
 
Contraceptives are the major products sold by CEMOPLAF, and CEMOPLAF contraceptives are 
92.5 percent of all contraceptives sold.  Table 3 shows the distribution of educational level, age 
group, sex, and partner status of CEMOPLAF contraceptive purchasers.   These data are 
contrasted in the same table with the 26 people who bought other brands of contraceptives. 
 
In terms of educational attainment, those who bought CEMOPLAF contraceptives had an overall 
lower level than persons buying other contraceptive brands.  Thirty-seven percent of 
CEMOPLAF contraceptive purchasers had less than secondary education versus only 19.2 
percent of other contraceptive brand buyers.  In terms of age, 70.3 percent of CEMOPLAF 
contraceptive buyers were in the 25 to 44 year age group.  In contrast, 50 percent of other brand 
buyers were in that age group.   Females were 63 percent of all CEMOPLAF contraceptive 
purchasers, and 69.2 percent of non-CEMOPLAF contraceptive buyers.  
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Table 3:  Profile of Contraceptive Purchasers by Source of Product 
SOURCE OF PRODUCTS 
CEMOPLAF OTHERS Characteristics of users 


























Total 100 319 100 26 
Age Group 
  <15 
15 – 24 
25 – 34 
35 – 44 

























































Total 100 314 100 25 
 
B.  Characterization Of CEMOPLAF Products Purchased 
 
1.  Types of Products Purchased 
 
Contraceptives account for 44.5 percent of all CEMOPLAF product sales, as shown in Table 4.  
Contraceptives are followed in sales volume by antispasmodics (15.4% of all CEMOPLAF 
sales), antibacterials/antimicrobials/antivirals (11.2%), cough suppressants (6.3%), laxatives 
(4.3%), anti-inflammatory drugs (3.8%), and cold remedies (3.5%).  The non-CEMOPLAF 
products most frequently purchased were:  analgesics (15.5%), antimicrobials/antivirals (14.2%), 
and anti-inflammatory drugs (13%).  These are drugs that could be more strongly promoted by 
CEMOPLAF to capture some of the market going to other brands of those drugs. 
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Table 4:  Types of Products Purchased in Pharmacies by Source 
SOURCE OF PRODUCTS 
CEMOPLAF OTHERS Types of Products* 
% N % N 
Contraceptives 
Antispasmodics 































































Total 100 719 100 10565 
*Classification of medicine products was done by CEMOPLAF medical consultants. 
 
2.  Types of Contraceptives Purchased 
 
A list of specific CEMOPLAF contraceptives purchased in the study pharmacies is shown in 
Table 5.  Oral contraceptives were by far the most frequently sold type of CEMOPLAF product, 
accounting for 52.8 percent of CEMOPLAF contraceptive sales, led by the brands Lo Femenal 
(29.7%) and Microgynon (14.1%).  OCs were followed by condoms at 29.7 percent, injectables 
at 17.5 percent, and barrier methods at 0.3 percent.     
 
Oral contraceptives accounted for one-half of all non-CEMOPLAF contraceptive sales, led by 
the brand Triquilar (19.2%).  The single most frequently purchased non-CEMOPLAF 
contraceptive was Norform vaginal tablets (34.6%).  The injectable contraceptive Gynodian 
comprised 15.4 percent of the non-CEMOPLAF contraceptive market.  No condoms were sold in 














Table 5:  Types of Contraceptives Purchased in Pharmacies by Source 
SOURCE OF PRODUCTS 
Type and Brand 



































































Total 100 100 
N = 320 26 
 
3.  Types of Pregnancy Tests Purchased 
 
Table 6 shows the types and sources of pregnancy tests purchased.  Of 17 pregnancy tests 
purchased by study subjects, 13 (76.5%) were CEMOPLAF brands.   
 
Table 6:  Types of Pregnancy Tests Purchased in Pharmacies by Source 
SOURCE OF PRODUCTS 
CEMOPLAF OTHERS Brand 



























4.  For Whom Product Was Purchased 
 
Table 7 shows that approximately half of all pharmaceutical purchases were made for people 
other than the purchaser him/herself, with men purchasing for themselves in 55 percent of the 
cases and females for themselves in 50.4 percent.  Purchases made for one’s spouse/partner 
accounted for 10.4 percent of male purchases and 4.7 percent of female purchases.  Twenty 
percent of female purchases were made for their own child, while this held true for about 10 
percent of men’s purchases.  For both men and women, purchases were frequently made for 
persons older than the purchaser him/herself, such as a mother/father, aunt/uncle, or grandparent 
(13% of purchases).  
 
Table 7:  For Whom Product Was Purchased, by Gender of Interviewee 
GENDER OF INTERVIEWEE 
For whom product was purchased 
Male (%) Female (%) 
Self 
Spouse or partner 
Son/daughter 
Another older person 
Another person of same age 
















Total 100 100 
N = 3970 4969 
 
Table 8 shows that pregnancy tests and non-contraceptive medicines were approximately divided 
among purchases for self and for others.  Contraceptives, on the other hand, were purchased for 
oneself in 81.7 percent of those cases.   
 
Table 8:  For Whom Pharmaceutical Product Was Purchased, by Type of Product 
 TYPE OF PRODUCT 






Medicine          
(%) 
Total             
(%) 
Self 81.7 46.2 49.3 65.0 
Other  18.3 53.8 50.7 35.0 
N = 300 13 306 619 
 
5.  Use of Physician Prescription for Pharmaceutical Purchase 
 
The effect of physician prescription on purchase of CEMOPLAF products is shown in Table 9.  
On average, 34.6 percent of all CEMOPLAF oral contraceptives and 28.9 percent of injectable 
contraceptives were purchased with a prescription.  Prescriptions were generally not used for 
condom purchases.  Among non-contraceptive CEMOPLAF products sold, an average of 26.1 
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percent were purchased with a physician prescription.  The large proportion of pharmaceutical 
products sold without a prescription is not altogether unusual for the Latin American region.  
This information can help CEMOPLAF identify which products are being successfully promoted 
through private physicians, and which could be more strongly promoted.   
  




prescription Total CEMOPLAF Products 
% % N 
Oral Contraceptives    
Lo Femenal 40.0 60.0 90 
Microgynon 17.8 82.2 45 
Nordette 50.0 50.0 4 
Duofen - 100 2 
Gynera 100 - 1 
Exluton - 100 2 
Total 34.6 65.4 144 
Injectables    
Topasel 46.7 53.3 45 
Mesigyna 40.0 60.0 15 
Depo Provera - 100 3 
Total 28.9 71.1 63 
Condom    
Total 1.1 98.9 92 
Vaginal Tablets    
Conceptrol 100 - 1 
Total 100 - 1 
Pregnancy Tests   
Pecolor PE - 100 6 
Detector 14.3 85.7 7 
Total 7.7 92.3 13 
Other CEMOPLAF Medicine   
Bisolvon 16.1 83.9 31 
Buscapina 6.9 93.1 72 
Bacterol 48.1 51.9 27 
Rotopar 100 - 6 
Compofen 27.3 72.7 11 
Clamox 87.5 12.5 8 
Mobic 33.3 66.7 12 
Ducolax 13.0 87.0 23 
Neogripal 9.1 90.9 11 
Trigentax 42.9 57.1 7 
Bacticel 83.3 16.7 6 
Doxifen - 100 1 
Invigan 100 - 2 
Materna 33 66.7 3 




6.  Reasons for Utilization of Study Pharmacies  
 
The data presented in Table 10 compares CEMOPLAF product purchasers with purchasers of 
non-CEMOPLAF products based on the reasons for shopping at the pharmacy in which they 
were interviewed.  Convenience was the major reason for using a particular pharmacy for 
purchase, accounting for 28.9 percent and 31.7 percent of the two groups, respectively.  From 
there, the two groups diverge somewhat in their stated motivations.  Seventeen percent of 
CEMOPLAF users purchased at that particular pharmacy because they perceived costs were 
lower, 14.5 percent because of random chance, 14.1 percent because they received better 
treatment there, and 8.1 percent because they had greater confidence in that pharmacy due to a 
personal relationship with the owner.  Among non-CEMOPLAF product purchasers, aside from 
the most important reason of convenience, 15.5 percent shopped at that particular pharmacy due 
to random chance, 13.0 percent because costs were lower, 12.0 percent because they had greater 
confidence, and 11.1 percent because they received better treatment there.  
 
Table 10:  Reasons Given for Using Pharmacy, Comparing Purchasers of CEMOPLAF 
and Non-CEMOPLAF Products  
SOURCE OF PRODUCTS 
Reasons for using pharmacy 
CEMOPLAF (%) OTHERS (%) 
Convenience 
Lower costs 
Better treatment  
Random chance 
More confidence (e.g. in quality) 
Habit or custom 
Has everything one could need 
Needed a product  
Only pharmacy available 
Has good products 
Hours of operation 
First time client 






























Total 100 100 
N = 619 8323 
 
The reasons for attending a particular pharmacy could vary by how close to the pharmacy they 
live or work.  In all, 63.5 percent of persons interviewed lived or worked near the pharmacy in 
which they were interviewed, while 36.5 percent came from outside the area.  Specific reasons 
why the pharmacy was used, comparing those who lived or worked nearby with those who did 
not, are shown on Table 11.  For 42.2 percent of those living or working nearby, pharmacy use 
was due to convenience for the buyer.  For 35.4 percent of those coming from outside the area, 
use of the pharmacy was due to random chance.  Seeking lower costs was the reason for 14.9 
percent of people coming from outside the areas versus 11.9 percent of those who live nearby, 
suggesting that some people were specifically drawn in for economic reasons.  People from 
outside the area were also attracted by the good treatment and the availability of most products.  
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Other reasons were distributed more or less randomly by place of residence.  These data suggest 
that the pharmacies that sell CEMOPLAF products are in desirable locations that are highly 
accessible to both local residents and outsiders.   
 
Table 11: Reasons for Use, Comparing Purchasers Living or Working near Pharmacy with 
Those Who Don’t 
LIVE OR WORK NEAR THE 
PHARMACY Reasons for using pharmacy 




Better treatment  
More confidence (e.g. in quality) 
Habit or custom 
Has everything one could need 
Has good products 
Only pharmacy available 
Needed a product  
Only one with the desired product 
Hours of operation 






























Total 100 100 
N = 5679 3263 
 
Table 12:  Reasons Given for Using Pharmacy, by City  
CITY IN ECUADOR  
Reasons for using pharmacy 




Better treatment  
More confidence (e.g. in quality) 
Habit or custom 
Has everything one could need 
Has good products 
Only pharmacy available 
Needed a product  
Only one with desired product 
Hours of operation 








































































Total 100 100 100 100 100 
N = 2993 2675 1746 942 586 
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For all pharmacy users, the reasons given as most important for having utilized that pharmacy 
had some interesting variations by city of residence that reflect differences in consumer culture.  
Table 12 shows that convenience was the major reason for using a pharmacy in all cities except 
Santo Domingo, a tropical inland city at sea-level, where lower costs and better treatment were 
the most important reasons.  In addition to Santo Domingans, Quiteños were less likely to use a 
pharmacy due to random chance as compared to other cities.  Rather, Quiteños, as well as 
Riobambans, had more of a propensity than people in other cities to use a pharmacy from habit 
or custom.  Ambato, a smaller-sized traditional town in the mountains, was the only one in which 
greater confidence in the pharmacy or its owners was one of the main reasons given for using the 
pharmacy in which they were interviewed. 
 
7.  Products Sought but Not Found 
 
A total of 167 (1.9%) of the 8,942 study subjects did not find a product for which they had gone 
to find at the pharmacy.  The list of products sought but not found at the pharmacies are listed by 
type in Table 13, classified by whether or not the pharmacy client had also bought a 
CEMOPLAF product.  The products most frequently not found were 
antibacterial/antimicrobial/antiviral medicines such as antibiotics, analgesics, anti-inflammatory 
medicines, vitamins, and cold remedies.  These data suggest the types of products that 
CEMOPLAF could use to expand the range of their market, especially since these five types of 
products coincide with the non-CEMOPLAF products that were most frequently purchased, as 
was shown on Table 4. 
 
Table 13:  Pharmaceutical Products Sought but not Found in Pharmacies by Study 
Population  
SOURCE OF OTHER PURCHASES 
Product not found 
CEMOPLAF (%) OTHERS (%) 
























Total 100 100 
N = 4 163 
 
 
IV.  Discussion and Recommendations 
 
In 1999, the CEMOPLAF project sold 21 contraceptive products and 22 other pharmaceutical 
products (some in various presentations such as capsules, syrups, and child and adult doses).  
Some of the products were purchased by CEMOPLAF from pharmaceutical companies 
(pregnancy tests, prescription drugs, etc.) and others were USAID donations (Lo-Femenal, 
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DMPA, IUDs, condoms).  The highest selling products were pills (300,000 per year), condoms 
(800,000 per year), injectable contraceptives (75,000 doses annually), and home pregnancy tests 
(50,000 tests per year).   The list of CEMOPLAF products and sales figures for 1999 is found in 
the appendices. 
 
The amounts of CEMOPLAF products reported as purchased in the current market survey are 
roughly proportional to the 1999 sales figures.  This helps to confirm the validity of the random 
selection procedures used to draw the sample of pharmacies and pharmacy clientele. 
 
A summary of market assessment findings and recommendations follow: 
 
1. Data showing differences in socioeconomic characteristics of pharmacy clientele between 
the five study cities in educational attainment, age, gender, and partner status reflect the 
general socioeconomic and cultural environment of each city.   It is a reminder that 
CEMOPLAF sales promotion strategies should take different approaches in different 
cities according to the socioeconomic profile of the local users.   
  
2. The study showed few differences in socioeconomic characteristics between pharmacy 
clients who purchased CEMOPLAF products versus purchasers of non-CEMOPLAF 
products, except for those related to higher concentration of contraceptive purchasers 
among CEMOPLAF buyers.  That is, CEMOPLAF purchasers were more frequently 
women of fertile age.  However, when only contraceptive purchasers are considered, the 
study results suggest that, compared to non-CEMOPLAF contraceptive purchasers, 
CEMOPLAF buyers are generally from a lower level of educational attainment, and that 
a relatively important reason for them to purchase at the pharmacy was to get a lower 
price.  Convenience and lower cost were the two major reasons why CEMOPLAF 
product buyers shopped at the pharmacy where they made a purchase.  These findings 
suggest that CEMOPLAF should continue to use promotional strategies that target lower 
socioeconomic populations.   At the same time, it is possible that a higher socioeconomic 
class of buyers could be targeted by special promotional efforts in order to further expand 
the market.    
 
3. The non-CEMOPLAF products most frequently purchased were analgesics, 
antibacterials/antimicrobials/antivirals, anti-inflammatory drugs, vitamins, and cold 
remedies.  These were also, not so coincidently, the items most frequently sought but not 
found.  CEMOPLAF already sells selected products in these categories.  Since there is a 
large demand for them, CEMOPLAF could move more strongly into these products to 
capture more of their market. 
 
4. Information on whether a medicine was purchased with a physician’s prescription is 
useful for monitoring how successful the CEMOPLAF program is in promoting specific 
pharmaceutical brands through private physicians.    
 
5. The large proportion of persons coming from outside the immediate neighborhood of the 
study pharmacies (36.5%) suggests that an expansion of pharmacies to new 
neighborhoods would capture additional clients who would be attracted to CEMOPLAF 
products by lower prices.  
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A.  Recommendations for future market profile studies 
 
As a final conclusion of the present market assessment of the CEMOPLAF customer profile, we 
can say that the same methods and variables used for this study should definitely be utilized for 
on-going periodic monitoring of the CEMOPLAF social marketing program.    The current study 
will serve as a baseline, and future efforts will show how customers are responding to marketing 
and pricing strategies employed by CEMOPLAF. 
 
The following are suggestions for future market profile studies: 
 
1. The questionnaire should include information on amount (i.e. number of doses) and price 
paid for each specific product purchased. 
2. It is suggested that the questionnaire used for this study be redesigned to ensure that 
information is captured about each medicine purchased by each interviewee.   For each 
medicine mentioned, questions should be asked about for whom is the medicine and if a 
prescription was used for its purchased.  
3. The question regarding for whom the product is purchased could use just three categories 
of possible responses: self, spouse or partner, or other.  This would shorten the time 
needed to fill out the questionnaire, and would especially simplify the data input and data 
analysis.   
4. Incentives or gifts should not be given to pharmacy survey respondents due to the risk of 
altering the normal purchasing habits of the population.  
5. The sample size should be increased if possible to allow a larger number of CEMOPLAF 
product buyers to fall into the sample so that analyses of their characteristics would have 
more statistical power, and more disaggregated analyses could be carried out. 
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STUDY III: QUALITY OF CARE ISSUES IN DELIVERY OF 
INJECTABLE AND ORAL CONTRACEPTIVES AND A 
PREGNANCY TEST IN ECUADOREAN PHARMACIES  
Authors: Federico R. León, James R. Foreit, Rosa Monge, Ana María Buller, Teresa de Vargas, 
Ernesto Pinto, & María del Rosario Naranjo  
 
I.  Introduction 
 
Reproductive health programs face a major challenge: to provide a greater variety of products 
and services to a rapidly increasing number of users. CEMOPLAF is a non-governmental 
organization (NGO) that operates a variety of reproductive health programs throughout Ecuador, 
including 21 reproductive health clinical centers and a social marketing program. Today, social 
marketing is the largest producer of CEMOPLAF’s revenue, accounting for approximately 36 
percent of gross income (approximately $67,000 per month). The program sells contraceptive 
and reproductive health products to pharmacies, physicians, and other distributors and non-
traditional outlets including liquor stores, hotels, motels and brothels. The program sells 34 
purchased products (pregnancy tests, prescription drugs, etc.) and USAID donated products (Lo-
Femenal, DMPA, IUDs, condoms). In terms of sales, the most important are pills (234,000 
cycles per year), condoms (800,000 packages of three per year), injectable contraceptives 
(100,000 doses per year), and home pregnancy tests (40,000 tests per year). 
 
CEMOPLAF has conducted evaluation and operations research (OR) to improve its social 
marketing program as an effective channel for delivering family planning and reproductive 
health services (e.g., Bratt et al., 1994, 1995, 1998). This research has been concerned with the 
economic aspects of the program. Another aspect of the program in need of research is the 
quality of the client-pharmacist interaction. CEMOPLAF is concerned that social marketing 
clients purchasing hormonal methods receive adequate information and management of method-
related side effects. CEMOPLAF clinical service norms require that users of hormonal methods 
receive counseling at acceptance and follow up, but no official policy governs quality of 
information that pharmacists should give to clients.  
 
This study was designed to obtain inputs for the design of interventions to enhance pharmacist 
information-giving behavior. The study objective was to collect observations on the client-
pharmacist interaction during the provision of oral and injectable contraceptives and pregnancy 
tests to identify strengths and weaknesses.  
 
 
II.  Methods 
 
CEMOPLAF medical staff decided the minimum information that pharmacists should be able to 
provide customers using DMPA (Depo-Provera), combined oral contraceptives, and a pregnancy 
test. On this basis, research staff constructed three Service Tests, one per product, to assess the 
extent to which pharmacists give information to customers. A Service Test consists of a set of 
instructions to perform as a simulated client (customer profile) and register behavioral 
observations on a checklist. The customer profile contains a set of instructions concerning what 
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the simulated client must say or ask the pharmacist. The checklist includes expected pharmacist 
behaviors whose presence must be verified by the simulated customer.  For contraceptives, these 
included talking about contraindications, giving instructions for correct use,  and side effects of 
the method.  
 
Female physicians were selected to conduct the Service Tests. In the case of the injectable 
contraceptive, the customer profile referred to a healthy 30 year-old woman who had a 1.5 year-
old child, was presently menstruating, was a user of the calendar rhythm method, and wanted to 
start using DMPA (Depo-Provera). She was trained to visit pharmacies as a simulated client and 
ask, “Can you please give me an injectable contraceptive?”  If the pharmacist offered several 
brands, she was expected to ask, “Which one would you recommend?” and choose one (Depo-
Provera, unless it was not offered). If the pharmacist did not spontaneously provide usage 
instructions, she would ask, “How should I use it?” and then, “What should I do if I forget to 
apply it in the expected date?” if the pharmacist did not provide this instruction. The simulated 
client was trained to use the checklist and register her observations as soon as she left the 
pharmacy. 
 
The client profile for combined oral contraceptives referred to a healthy woman between 25 and 
30 years who had a 1.5 year-old child, was presently menstruating, was a user of the calendar 
rhythm method, and wanted to start taking pills. She was trained to visit pharmacies as a 
simulated client and ask, “Can you please give me a package of contraceptive pills?” If the 
pharmacist offered several brands, she was trained to ask, “Which one would you recommend?” 
and choose one. If the pharmacist did not spontaneously provide usage instructions, she would 
ask, “How should I take them?” and then, “What should I do if I forget to take them every day?” 
if the pharmacist did not provide this instruction.  
 
Finally, the client profile for the pregnancy test referred to a young woman (17 to 30 years old) 
that suspected she was pregnant and wanted to rule out this possibility using a pregnancy test. 
She was trained to visit pharmacies as a simulated client and ask, “Can you please give me a 
pregnancy test?” If the pharmacist offered several brands, she was expected to ask, “Which one 
would you recommend?” and choose one. If the pharmacist did not spontaneously provide usage 
instructions, she would ask, “How should I use it?” As in the two previous cases, the simulated 
client was trained to use the checklist and register her observations as soon as she left the 
pharmacy. 
 
The population of the study included all the pharmacies that were clients of CEMOPLAF in five 
Ecuadorean cities. Stratified random sampling was used to choose 15 pharmacies in Guayaquil 
and 15 in Quito (five each from northern, central, and southern city areas). In Ambato and 
Riobamba, 5 pharmacies were randomly chosen in each city. Ten were chosen in Santo 
Domingo. One simulated client visited the 50 pharmacies requesting DMPA, another requesting 












Injectable contraceptives were available in the 50 pharmacies. Figure 1 describes the observed 
flow of client-pharmacist interactions. Of the 50 pharmacists involved, 41 offered the simulated 
client the option to choose the brand. Only 9 pharmacists offered just one brand to the client. 
(The study did not ascertain whether this was due to the lack of alternative brands in stock or 
preferences of the pharmacists.)  Regardless of number of brands offered, 28 pharmacists 
spontaneously offered information about the injectable contraceptive(s) and 22 failed to do so. 
When the simulated client asked for information she received it in all cases.  
 
Table 1 presents specific information per item of the checklist taking into account the phase of 
the client-pharmacist interaction. Phase A mainly encompasses the pharmacist’s spontaneous 
initiatives; the only request from the client in this phase concerned the guidance to choose one of 
the brands. In Phase B, the pharmacist was responding to the client’s specific request for usage 
instructions. In Phase C, the pharmacist responded to the client’s request for advice concerning 
what to do if she forgot to apply the injection in the due date.  
 
About one-third of the total number of pharmacists spontaneously stated prices and asked the 
client whether she was a new user. These figures increased to almost one-half in the second 
phase of the client-pharmacist interaction. At the end of the third phase, information concerning 
prices was given to the client in more than three fourths of the cases. The only question asked to 
screen the client for contraindications was whether she was menstruating (to rule out pregnancy).  
Twenty-two pharmacists failed to ask this question. 
  
About one-third of the pharmacists spontaneously informed the client that the injection is applied 
the first time when the woman is menstruating and then every three months (Phase A). When the 
client asked for usage instructions, 90 percent or more of the pharmacists referred to the presence 
of menstruation for the first injection and the 3-month interval between injections.  Only when 
the client asked specifically what to do if she forgot an injection did some of the pharmacists 
address the issue and the ensuing risk of pregnancy.  Pharmacists did not talk about the inserts 








Figure 1. Injectable:  Distribution of Cases in the Client – Pharmacist Interaction Dynamics






brand do you want?





























USER: Chooses one: _______
USER: How shall I use it?
USER: What should I do if the injection is not administered in the expected date?
USER: Buys the injection or declines buying it
END
9 12 29 0
5 4 5 7
7 22 0
5 2 13 9
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Table 1. Injectable: Information given/asked by pharmacist in each phase of 
interaction with client,    n=50 




1 Price 16 4 22 
2 Is this your first time? 20 9 0 
 Contraindications    
3 Check it with your physician 2 0 0 
4 Pregnancy 1 0 0 
5 Are you menstruating? 14 14 0 
6 Non-menstrual vaginal bleeding 1 2 0 
7 Hard formations in the breast or breast cancer 0 0 0 
 Usage Instructions:    
8 Injection administered every three months 19 27 0 
9 First injection administered during menstruation 12 33 0 
10 Forgetfulness 1 4 12 
11 Risk of pregnancy 1 3 24 
12 Reading instructions 0 0 0 
 Side Effects     
13 Menstruation may be irregular or spotting may be observed 3 1 0 
14 There may be lack of menstruation 0 0 0 
15 Temporary infertility after discontinuation 0 0 0 
 
B.  Pills 
 
Pills were available in the 49 pharmacies of the sample (there was 1 missing case). Figure 2 
describes the observed flow of client-pharmacist interactions. Of the 49 pharmacists involved, 40 
offered the simulated client the option to choose the brand. Only 9 pharmacists offered just one 
brand to the client, and this study did not ascertain whether this was due to the lack of alternative 
brands in stock or preferences of the pharmacists. Regardless of number of brands offered, 16 
pharmacists spontaneously offered information about the pills  and 31 failed to do so. When the 
simulated client asked for information, she received it in all cases. There were also two 
pharmacists that offered other methods. 
 
Table 2 presents specific information per item of the checklist taking into account the phase of 
the client-pharmacist interaction. Phase A mainly encompasses the pharmacist’s spontaneous 
initiatives; the only request from the client in this phase concerned the guidance to choose one of 
the brands. In Phase B, the pharmacist was responding to the client’s specific request for usage 
instructions. In Phase C, the pharmacist responded to the client’s request for advice concerning 






Figure 2 Pill:  Distribution of Cases in the Client – Pharmacist Interaction Dynamics






brand do you want?





























USER: Chooses one: _______
USER: How shall I use them?
USER: What should I do if I don´t take them everyday?
USER: Buys pills or declines buying them
END
9 3 37 0
3 6 1 2
16 19 2





Table 2. Pills: Information given/asked by pharmacist in each phase of interaction 
with client,       n=49 




1 Price 24 3 21 
2 Is this your first time? 12 9 0 
 Contraindications    
3 Check it with your physician 2 1 0 
4 Are you menstruating?  8 7 0 
5 Pregnancy 0 1 0 
6 Breastfeeding 0 1 0 
7 Non-menstrual vaginal bleeding 0 0 0 
8 Hard formations in the breast or breast cancer 1 0 0 
9           Cardiovascular diseases 1 0 0 
10 Liver diseases 1 1 0 
 Usage Instructions:    
11 Every day 6 39 1 
12 Use of package 4 25 2 
13 Forgetfulness 3 3 25 
14 Risk of pregnancy 0 2 21 
15 Restart 1 1 5 
16 Reading instructions 0 1 0 
 Side Effects     
17 Headache  0 1 0 
18 Sickness 0 0 0 
19 Nervousness 0 0 0 
 
As shown by Table 2, half of all pharmacists stated prices and a quarter asked the client whether 
she was a new user, both in the first phase. Information about contraindications or usage 
instructions was very low in this phase; the most frequently reported items  (“are you 
menstruating?” and “pills must be taken every day”) were mentioned by only 15 percent of 
pharmacists. 
 
When the client asked for usage instructions (Phase B), 80 percent of the pharmacists said that 
pills must be taken every day and about 50 percent referred to the correct use of the package. 
Only when the client asked specifically what to do if she forgot to take a pill, did some of the 
pharmacists address the issue and the ensuing risk of pregnancy. Pharmacists did not talk about 
restarting pills or about inserts within the product package. Information given to the client about 





C. Pregnancy Test  
 
There were three missing cases.  Pregnancy tests were sold in 46 pharmacies.  Figure 3 shows 
the flow of client-pharmacist interactions.  Of the 46 pharmacies, 29 offered the simulated client 
the option to choose the pregnancy test brand while 17 pharmacists offered one brand to the 
client. (The study did not ascertain whether this was due to the lack of alternative brands in stock 
or preferences of the pharmacists.)  Regardless of number of brands offered, it can be observed 
that the great majority of pharmacists (45) did not spontaneously offer information about the 
pregnancy test.  When the simulated client asked for information, she received it in all cases.  
 
In this Service Test, Phases A and C mainly encompasses the pharmacist’s spontaneous 
initiatives, while Phase B encompasses the pharmacist’s answers to the client’s question about 
usage instructions (see Figure 3). 
 
Most pharmacists stated prices in the first phase and about 1/3 in the second phase.  Only two 
pharmacists gave instructions spontaneously (Phase A), whereas half of the cases gave 
instructions or told the simulated client to read them in the second phase, that is, after the 
simulated client specifically asked how to use the product (Table 3).  Questions about the 






Figure 3. Distribution of Cases in the Client – Pharmacist Interaction Dynamics






brand do you want?
PHARMACIST:  There 




























USER: Chooses one: _______
USER: How shall I use it?
USER: Buys the pregnancy test or declines buying it
END
17 13 16 1
0 17 0 13
1 15 0





Table 3. Pregnancy Test: Information given/asked by pharmacist in each phase of 
interaction with client,     n=46 




1 Price 27 17 3 
2 How long has your menstrual period been missing 0 0 0 
3 Check it with your physician 0 0 0 
 Usage Instructions (depending on the test)    
4 Gives instructions 2 24 0 
5 Reads instructions 0 24 0 
  
 
IV.  Discussion 
 
This study revealed that pharmacists behave very much like clinical providers of family planning 
methods: they tend to formulate questions concerning the menstrual status of the client and give 
her usage instructions but little or no information about side effects and contraindications (León 
et al., 1999).  
 
On the other hand, the study showed that the pharmacist’s asking standard questions and giving 
usage instructions are increased when the client formulates specific questions. This suggests an 
intervention to enhance provider’s information-giving behavior: stimulating the client to 
formulate questions, which can be done by placing posters with appropriate messages within the 
pharmacies. 
 
The same intervention could be used to change pharmacist information-giving behavior 
concerning contraindications and side effects. In this case, the posters would have to specifically 
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CONFERENCE:  SUSTAINABILITY AND SOCIAL MISSION:  
SHARING LESSONS FROM RESEARCH AND PRACTICE 
Author:  Kristina Lantis 
 
I.  Introduction 
 
The conference, Sustainability and Social Mission: Sharing Lessons from Research and Practice, 
was held May 16 – 18, 2001 in Quito, Ecuador.  Over 80 attendees representing more than 40 
organizations and 12 countries met to discuss how to improve financial sustainability through the 
use of business practices while continuing to fulfill their social mission of serving the poor.  The 
conference was sponsored by CEMOPLAF of Quito, Ecuador, and by two United States Agency 
for International Development (USAID) funded projects, Frontiers in Reproductive Health and 
Commercial Market Strategies (CMS). 
 
 
II.  Attendees 
 
More than 80 individuals registered to attend the conference.  They represented over 40 family 
planning organizations, research organizations, pharmaceutical companies, and donors.  A 
complete list of registrants can be found in the appendix. 
 
 
III.  Conference Objectives 
 
The conference objectives were to: 
 
• Share sustainability research and lessons learned;  
 
• Share experiences of NGOs that have attempted to improve the sustainability of programs 
while maintaining their commitment to social mission; and 
 
• Provide NGOs and companies that market reproductive health products the opportunity 
to explore the possibility of commercial agreements. 
 
 
IV.  Agenda 
 
The conference consisted of three full days of panel presentations, question and answer sessions, 
roundtable sessions and open discussions. Presentations were given in both Spanish and English 
with simultaneous translation. A copy of the agenda can be found in the appendix. 
 
A.  Day One 
 
The conference began with a welcome and statement of objectives from representatives of the 
three sponsoring organizations: Teresa de Vargas, CEMOPLAF; Alvaro Monroy, CMS; and 
Ricardo Vernon, FRONTIERS. 
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The first panel, Sustainability vs. Social Mission: What do programs need to do?, discussed the 
definitions of both social mission and sustainability, their compatibility and the challenges NGOs 
and the commercial sector will face with regard to sustainability and social mission. 
 
Following a discussion of Panel 1, four discussion groups were formed for participants to discuss 
donor expectations, barriers to commercial growth, definition of social mission and private 
sources of funding.   
 
The second panel discussed research findings from Ecuador, Guatemala, Honduras, and El 
Salvador on the impact of sustainability activities on program utilization and client profile.  The 
panel was followed by a 45-minute open discussion of agency experiences with the impact of 
price increases on utilization. 
 
B.  Day Two 
 
Two panels took place in the morning of the second day.  The first discussed various market 
research tools including market research surveys, willingness to pay surveys, psycho-behavioral 
market segmentation and focus groups and other qualitative techniques.  The second panel, 
Calculating and Using Cost Information, discussed calculating costs, price setting, profitability 
analysis and cross-subsidies. Both panels were followed by half-hour discussion sessions. 
 
Panelists in the afternoon discussed marketing strategies for reproductive health services such as: 
in-reach and missed opportunities, quality, diversification, the addition of commercial marketing 
and selling to the commercial sector. 
 
Representatives from CMS, FRONTIERS and The Futures Group International (TFGI) provided 
participants with assistance in obtaining research tools and discussed opportunities for research 
collaboration at a round table session. 
 
C.  Day Three 
 
The final day of the conference began with a presentation on alternative financing mechanisms. 
Representatives from various commercial sector companies, including CPR, Drogueria Inti, 
General Electric Health Systems and Schering, discussed “What can the commercial sector offer 
NGOs to make them more sustainable?” in Panel 6. 
 
The final two round tables of the conference discussed the experiences of Latin American 
agencies with products and services, both profitable and non-profitable. 
 
The conference closed with comments and conclusions from Alvaro Monroy, CMS and Teresa 







V. Sustainability Snapshot 
 
Organizations attending the conference were asked to complete a form concerning their budget-
structure (percent donor vs. percent self-generated) and future of donor funding.   
 
• 11/20 organizations indicated they were more than 50 percent self-sustainable (more than 
50 percent of their budget was self-generated). 
 
• Of those >50 percent self-sustainable organizations, 2/11 said their donor funding would 
remain stable and 9/11 indicated that their donor funding would be decreasing. 
 
• 9/20 organizations were less than 50 percent self-sustainable (more than 50 percent of 
their budget came from donor funds), of these organizations 5 predicted decreasing donor 
funding, 3 predicted their donor funding would remain stable and one predicted its donor 
funding would increase. 
 
• 19/20 organizations indicated their donor funding would either remain stable (5) or would 
decrease (14).  The one organization that indicated its donor funding would increase is 
also 0 percent self-sustainable. 
 
• When funding structure information was combined for all 20 organizations and averaged, 
45 percent of the budget was donor funded and 55 percent was self-generated.   
 
• 2/20 organizations indicated that 100 percent of their budget came from donor funds.  If 
these two organizations are not included, the average budget structure for the remaining 
18 is: 39 percent donor funded and 61 percent self-generated. 
 
 
VI. Conference Evaluation 
 
Results of the conference evaluation are available in the appendix. More than eighty percent of 






Appendix 1 – Allocation Decisions and Other Assumptions 
 
1. Allocation of Joint Expenses in the Quito Region 
 
Staff Meetings – if the expense was less than S/. 300,000, it was allocated to the Quito sales 
agents; otherwise it was allocated to all sales agents. 
 
Courses and Seminars, Promotional Material, Promotion Activities – these expenses were 
allocated equally to all sales agents. 
 
Travel and Per diem – these expenses were allocated equally to non-Quito sales agents. 
 
Vehicle Maintenance - these expenses were allocated equally to Quito sales agents. 
 
2. Assumptions underlying Capital Costs 
 
We assumed that each sales agent had access to a computer for record-keeping (invoices, 
accounts receivable and payable, etc.), and a basic suite of furniture including a desk, a chair and 
a filing cabinet.  The SM program also owns a vehicle that is used exclusively in the Quito 
region. 
 
The table below presents information used to calculate annualized cost for capital items. 
 
Item Purchase Price Useful Life Discount Rate 
Computer/printer 1,000 5 years 10% 
Office Furniture 200 10 years 10% 
Vehicle – Vitara 11,063 10 years 10% 
 
3. Calculation of Equivalent Rent 
 
An estimate of average rental cost per square meter was needed to compute a monthly 
“equivalent rent” for the clinics that CEMOPLAF owns.  This estimate was generated using the 
data in the following table. 
 
Clinic Monthly Rent (S/.) Clinic Area (M2) Cost per M2 
Tulcan 1,000,000 120 8,333 
Ibarra 900,000 200 4,500 
Quininde 530,000 130 4,077 
Quito – COP 1,200,000 147 8,163 






CEMOPLAF Social Marketing Program Sales During 1999 




%  PRODUCT TOTAL 
NUMBER 
% 
IUD's  OTHER PRODUCTS cont.   
Tcu 380 A ( units) 64746 9.96  Bacterol 20 capsules 1588 0.24 
Spirals 1 0.00  Bacterol forte x 10 capsules 3724 0.57 
    Bacterol susp. 3500 0.54 
ORAL 
CONTRACEPTIVES 
   Doxifen cream 2590 0.40 
Marvelon (dose) 2807 0.43  Doxifen óvulos 2822 0.43 
Microgynon (box x 3) 19161 2.95  Doxifen Dual 299 0.05 
Microgynon CD ( box x 3) 19499 3.00  Bacticel Simple 88 0.01 
Lo Femenal (dose) 226568 34.85  Bacticel Forte 149 0.02 
Exluton (dose) 13018 2.00  Bacticel Susp 189 0.03 
Nordette (dose) 3454 0.53  Invigan 1118 0.17 
Trinordiol (dose) 1591 0.24  Compofen 2886 0.44 
Minulet (dose) 6057 0.93  Mobic 7.5 1458 0.22 
Gynera (dose) 3906 0.60  Mobic 15 998 0.15 
Gynera CD 3034 0.47  Mobic syringes 760 0.12 
Mercilon 1717 0.26  Bisolvon 9304 1.43 
Femiane 969 0.15  Buscapina simple 1132 0.17 
Harmonet 426 0.07  Buscapina (tablets) 6918 1.06 
    Buscapina (syringe) 5883 0.90 
INJECTABLES    Buscapina plus (capsules) 4586 0.71 
Depo provera 3787 0.58  Kiddi 3219 0.50 
Mesigyna 28234 4.34  Pharmaton 2403 0.37 
Topasel 43113 6.63  Pharmaton complex 2996 0.46 
    Cutamycon cream 1263 0.19 
BARRIER    Cutamycon Vag. Tab. 493 0.08 
Panther (units) 37417 5.76  Rotopar tab. 3766 0.58 
Protektor (box x 3) 23282 3.58  Rotopar susp. 3607 0.55 
Conceptrol (units)  0.00  Trigentax cream 8260 1.27 
    Tinidameb 897 0.14 
OTHER PRODUCTS     Premarin 0.625 1316 0.20 
Detector x 25 13263 2.04  Premarin cream 549 0.08 
Detector x 10 14896 2.29  Materna 5140 0.79 
Detector Gold 3938 0.61  Dulcolax 1853 0.29 
Pregcolor 165 0.03  Neogripal x 12 868 0.13 
Pregcolor Premium 17783 2.74  Neogripal x 60 270 0.04 
Clamox óvulos 3823 0.59  Neogripal syrup 1069 0.16 
Clámox cream 2042 0.31  Neogripal drops 1437 0.22 






CONFERENCE AGENDA: SUSTAINABILITY AND SOCIAL MISSION 
 
Day 1 Agenda: Wednesday, May 16, 2001 
8:00 a.m. – 9:00 a.m. Registration 
 
 
9:00 a.m. – 9:30 a.m. Welcome and 
Conference Objectives 
Teresa de Vargas, CEMOPLAF 
Alvaro Monroy, CMS 
Ricardo Vernon, FRONTIERS 
 




9:30 – 9:45 
 
9:45 – 10:00 
 
 
10:00 – 10:15 
 
10:15 – 10:30 
Panel 1: Sustainability vs. Social 
Mission: What Do Programs Need 
to Do?   
Definition of sustainability 
 
Are sustainability and social 
mission compatible? 
 
Private sector social mission 
 
NGO and commercial sector 
challenges 
 




Alvaro Monroy, CMS 
 
Guy Stalworthy, PSI 
 
 
Santiago Cordova, CELSAM 
 
Karen Foreit, TFGI 
10:30 a.m. – 11:00 a.m. Discussion 
 
 
11:00 a.m. – 11:15 a.m. Coffee Break 
 
 
11:15 a.m. – 12:15 p.m. Discussion Groups    
 
How much do we expect from 
donors and how much must we 
raise in non-donor funds to 
survive?   
 
Barriers to commercial sector 
growth.   
 
How do LAC NGOs define social 
mission?   
 
Private donors and foundations as 















Maricela Durá, MEXFAM 
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12:15 p.m. – 1:15 p.m. Discussion Group Presentations Moderator: Jim Foreit, 
FRONTIERS 
 
1:15 p.m. – 2:30 p.m. Lunch 
 
 













3:00 – 3:15 
Panel 2: Research Findings on the 
Impact of Sustainability Activities 
on Program Utilization and Client 
Profile.   
 
Socio-economic profiles of NGO 
clients in Ecuador, Guatemala, 
Honduras and El Salvador.  
 
Impact of price increases on client 
profiles.  
 
Impact of sustainability activities 
on demand for services and client 
profile in CEMOPLAF  
 









Zonia Aguilar, APROFAM 
 
 
Ernesto Pinto, CEMOPLAF 
3:15 p.m. – 4:00 p.m. Open Floor Discussion of Agency 
Experiences with the Impact of 
Price Increases on Utilization 
 




Day 2 Agenda: Thursday, May 17, 2001 
9:00 a.m. – 10:00 a.m. 
 
9:00 – 9:15 
 
9:15 – 9:30 
 
9:30 – 9:45 
 
9:45 – 10:00 
Panel 3: Market Research Tools 
 
Market research survey 
 




Focus groups and other qualitative 
techniques 
 
Moderator: John Bratt, FHI 
 
José Alvarez, CHSP 
 
Jim Foreit, FRONTIERS 
 
Ratha Loganathan, CMS 
 
Martha Mérida, PROSALUD. 
10:00 a.m. – 10:30 a.m. Discussion  
 
10:30 a.m. – 10:45 a.m. Coffee Break  
 
10:45 a.m. – 11:45 a.m. 
 
 
Panel 4: Calculating and Using 
Cost Information   
 




10:45 – 11:00 
 
11:00 – 11:15 
 
 
11:15 – 11:30 
 
 
11:30 – 11:45 
Calculating Costs 
 
Price setting using cost and other 
criteria. 
 
Profitability analysis of 
CEMOPLAF marketing program 
 
When do cross-subsidies work? 
 





Rosario Naranjo, CEMOPLAF 
 
 
Julia Walsh, BIG. 
11:45 a.m. – 12:15 p.m. Discussion 
 
 
12:15 p.m. – 1:30 p.m. Lunch 
 
 
1:30 p.m. – 2:45 p.m. 
 
 
1:30 – 1:45 
 
 
1:45 – 2:00 
 
 
2:00 – 2:15 
 
 
2:15 – 2:30 
 
 
2:30 – 2:45 
Panel 5: Marketing Strategies for 
Reproductive Health Services   
 
In-reach and missed opportunities 
to provide more services. 
 






Adding commercial marketing to 
NGO activities. 
 
Selling to the commercial sector. 
 
Moderator: Carlos Morlacchi, 
ASHONPLAFA 
 
Ricardo Vernon, FRONTIERS 
 
 
Miriam Becerra/Agustín Cuesta, 
APROFE 
 
Brian Mitchell, BIG 
 
 






2:45 p.m. – 3:15 p.m. Discussion  
 
 
3:15 p.m. – 4:15 p.m. Round Tables:  Getting Technical 
Assistance for Research.  
 
Representatives of CMS, 
FRONTIERS and TFGI will 
provide help to participants in 
obtaining research tools and will 
discuss possibilities for research 
collaboration with donors and 
service delivery agencies. 
 
José Alvarez, CHSP 
 
Ratha Loganathan, CMS 
 
Jim Foreit/Ricardo Vernon, 
FRONTIERS 
 
John Bratt, FHI 
 




Day 3 Agenda: Friday, May 18, 2001 
8:45 a.m. – 9:15 a.m. Alternative Financing Mechanisms Carlos Carrazana, Summa 
Foundation 
 
9:15 a.m. – 9:45 a.m. Discussion  
 




9:45 – 10:15 
 
10:15 – 10:45 
 
10:45 – 11:15 
 
11:15 – 11:45 
 
11:45 – 12:15 
Panel 6: What Can the 
Commercial Sector Offer NGOs to 






















Alan Forney and Ayappan M 
 
Marco Egas 
12:15 p.m. – 1:15 p.m. Round Table: Profitable and Non-
profitable Products: The 















1:15 p.m. – 1:35 p.m. Discussion  
1:35 p.m. – 2:35 p.m. Lunch  
2:35 p.m. – 3:35 p.m. Round Table: Profitable and Non-
profitable Services: The 














Teresa de Vargas 
Maricela Durá 
Martha Mérida 
3:35 p.m. – 3:55 p.m. Discussion 
 
 
3:55 p.m. – 4:25 p.m. Conclusions and Closing 
 
Alvaro Monroy, CMS 
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EVALUATION:  SUSTAINABILITY AND SOCIAL MISSION CONFERENCE 
 
TOTAL DE PARTICIPANTES EVALUADOS: 47 
 
 


















1. Alcance de los objetivos 18 24 5   89% 
2. Contenido de la Conferencia 21 21 5   89% 
3. Estructura y secuencia 21 19 5 2  85% 
4. Profundidad 11 27 9   81% 
5. Utilidad y aplicación de los temas  16 25 5 1  87% 
II.   EVALUACIÓN A LOS FACILITADOROS 
1. Dominaron el tema 22 19 6   87% 
2. Capacidad didáctica 18 18 11   77% 
3. Forma en que propiciaron la 
participación del grupo 20 15 11 1  74% 
4. Respondieron a las preguntas de los 
participantes 19 21 7   85% 
III.  EVALUACIÓN DEL PARTICIPANTE 
1. Adquirí habilidad y conocimientos 16 25 5 1  87% 
2. Me integré al grupo 17 22 6 2  83% 
3. Puse atención y participé 18 26 3   93% 
4. Demostré interés y esfuerzo 22 23 2   96% 
IV.  EVALUACIÓN DE LOGÍSTICA 
1. Calidad del material didáctico 26 18 3   94% 
2. Condiciones físicas y ambientales 42 3 1 1  96% 
3. Duración de la conferencia 34 9 2   91% 
4. Horario de la conferencia 32 13 2   96% 




- Felicitación – Gracias! 
- Ninguna – Felicitaciones 
- Excelente conferencia 
- Felicitaciones a CEMOPLAF 
- Continúen adelante 
- Gracias por la hospitalidad 
- En algunos temas sugiero mayor profundidad 
- Menos presentaciones y más grupos de 
discusiones como el primer día 
- Volver a organizar otra conferencia con más 
participación del grupo 
- En otra conferencia pedir la participación directa 
de las ONGs que aportan con ayuda económica 
- Publicar los resultados 
- Thank you for the excellent translation!  Thank 
you!! 
 
- Favor de repartir las presentaciones antes de las 
ponencias pues permite hacer anotaciones 
coherentes y oportunas.  ¡Gracias por tanta 
amabilidad al personal de apoyo! 
- Dar secuencia para nuevas reuniones para 
intercambio de experiencias 
- Quizá muy apretada la agenda 
- Agradecimiento por el evento tan importante en 
organización, contenido y objetivos 
- Hacerla en 2 años, profundizar en la reducción 
de costos.  Excelente conferencia 
- Felicitaciones y realizar la próxima conferencia 
CEMOPLAF did an outstanding job with 
organization, I only wish there had been more 
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Ernesto Pinto, CEMOPLAF 
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Jim Foreit, FRONTIERS 
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Ratha Loganathan, CMS 
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Experiencia de PROSALUD 
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A Profitability Analysis of the CEMOPLAF 
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Foundation 
  
How can FPAs earn money out of the condom 
business in order to finance other social 
activities? 
Michael Kesserling, CPR 
  
Productos y Servicios Rentables y no 
Rentables in ASHONPLAFA 
Carlos Morlacchi, ASHONPLAFA 
  
Productos y Servicios Rentables y no 
Rentables 
Ney Costa, BEMFAM 
 
  
Productos y Servicios Rentables y no 
Rentables: La experiencia de CEMOPLAF 
Teresa de Vargas & Jenny Vásquez, 
CEMOPLAF 
  
Productos y Servicios Rentables y no 
Rentables 
Paolo Marangoni, APROFE 
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